biostudies-literatureUnknown8(5)Kim SH<h4>Importance</h4>Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.<h4>Objective</h4>To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI.<h4>Design, setting, and participants</h4>This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac centeJAMA network opene2511297https://www.ebi.ac.uk/biostudies/studies/S-EPMC12093190biostudies-literatureDeescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial.PMC12093190Her SHTALOS-AMI InvestigatorsKim SWLim SYoon MHChoi IJLee MHuh SHPark KMJang JSLee KYKim KSOh JHKim CJByeon JKim SHSung KCCho JMPark SHLee JHDo JHChang KCho YHHwang BHCho BRLee SHBaek JYJung SSPark JSPark MWKim WShin WSChoo EHPark CSKo JSCha KSShim BJSa YKKim DBCho CHChung KTJeong MHChoi YSfalseDeescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial.<h4>Importance</h4>Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.<h4>Objective</h4>To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI.<h4>Design, setting, and participants</h4>This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac cente2025-01-01T00:00:00Z2025 May2026-06-01T10:22:31.288Z2026-04-08T11:23:21.772ZS-EPMC120931904039255410.1001/jamanetworkopen.2025.11297